• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2型抗体、其诊断用途及其在疫苗开发中的潜力。

The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.

作者信息

Hajissa Khalid, Mussa Ali, Karobari Mohmed Isaqali, Abbas Muhammad Adamu, Ibrahim Ibrahim Khider, Assiry Ali A, Iqbal Azhar, Alhumaid Saad, Mutair Abbas Al, Rabaan Ali A, Messina Pietro, Scardina Giuseppe Alessandro

机构信息

Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kota Bharu 16150, Kelantan, Malaysia.

Department of Zoology, Faculty of Science and Technology, Omdurman Islamic University, Omdurman P.O. Box 382, Sudan.

出版信息

Vaccines (Basel). 2022 Aug 18;10(8):1346. doi: 10.3390/vaccines10081346.

DOI:10.3390/vaccines10081346
PMID:36016233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9412318/
Abstract

Antibodies (Abs) are important immune mediators and powerful diagnostic markers in a wide range of infectious diseases. Understanding the humoral immunity or the development of effective antibodies against SARS-CoV-2 is a prerequisite for limiting disease burden in the community and aids in the development of new diagnostic, therapeutic, and vaccination options. Accordingly, the role of antiviral antibodies in the resistance to and diagnosis of SARS-CoV-2 infection was explored. Antibody testing showed the potential in adding important diagnostic value to the routine diagnosis and clinical management of COVID-19. They could also play a critical role in COVID-19 surveillance, allowing for a better understanding of the full scope of the disease. The development of several vaccines and the success of passive immunotherapy suggest that anti-SARS-CoV-2 antibodies have the potential to be used in the treatment and prevention of SARS-CoV-2 infection. In this review, we highlight the role of antibodies in the diagnosis of SARS-CoV-2 infection and provide an update on their protective roles in controlling SARS-CoV-2 infection as well as vaccine development.

摘要

抗体(Abs)是重要的免疫介质,也是多种传染病中强大的诊断标志物。了解体液免疫或针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)产生有效抗体是限制社区疾病负担的先决条件,有助于开发新的诊断、治疗和疫苗接种方案。因此,研究了抗病毒抗体在抵抗和诊断SARS-CoV-2感染中的作用。抗体检测显示出在为2019冠状病毒病(COVID-19)的常规诊断和临床管理增加重要诊断价值方面的潜力。它们在COVID-19监测中也可发挥关键作用,有助于更好地了解该疾病的全貌。几种疫苗的研发以及被动免疫疗法的成功表明,抗SARS-CoV-2抗体有潜力用于治疗和预防SARS-CoV-2感染。在本综述中,我们强调了抗体在诊断SARS-CoV-2感染中的作用,并提供了关于它们在控制SARS-CoV-2感染以及疫苗研发中的保护作用的最新情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad34/9412318/2ff9d3990128/vaccines-10-01346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad34/9412318/d38bb80c11c5/vaccines-10-01346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad34/9412318/2ff9d3990128/vaccines-10-01346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad34/9412318/d38bb80c11c5/vaccines-10-01346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad34/9412318/2ff9d3990128/vaccines-10-01346-g002.jpg

相似文献

1
The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development.严重急性呼吸综合征冠状病毒2型抗体、其诊断用途及其在疫苗开发中的潜力。
Vaccines (Basel). 2022 Aug 18;10(8):1346. doi: 10.3390/vaccines10081346.
2
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.杂合免疫改变了 SARS-CoV-2 mRNA 疫苗诱导免疫的 Fc 效应子质量。
mBio. 2022 Oct 26;13(5):e0164722. doi: 10.1128/mbio.01647-22. Epub 2022 Aug 24.
3
A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.COVID-19 中单抗的研究进展:在免疫治疗、疫苗开发和病毒检测中的作用。
Hum Antibodies. 2021;29(3):179-191. doi: 10.3233/HAB-200441.
4
Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study.两种不同 SARS-CoV-2 疫苗在一组医护人员中的体液和细胞免疫反应:一项观察性研究。
J Immunol Methods. 2024 May;528:113665. doi: 10.1016/j.jim.2024.113665. Epub 2024 Mar 14.
5
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.健康受试者对 mRNA COVID-19 疫苗的抗体反应差异。
Microbiol Spectr. 2021 Sep 3;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. Epub 2021 Aug 4.
6
SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.埃塞俄比亚霍瓦萨地区学龄儿童中的 SARS-CoV-2 感染和 mRNA 疫苗诱导的体液免疫。
Front Immunol. 2023 Jun 15;14:1163688. doi: 10.3389/fimmu.2023.1163688. eCollection 2023.
7
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
8
Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.在 SARS-CoV-2 初免和既往感染人群中,BNT162b2 mRNA 疫苗对细胞和体液免疫应答的动力学和持久性:加强针和突破性感染的影响。
Front Immunol. 2022 May 31;13:863554. doi: 10.3389/fimmu.2022.863554. eCollection 2022.
9
Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.SARS-CoV-2 特异性体液免疫的特性及其潜在的应用和治疗前景。
Cell Mol Immunol. 2022 Feb;19(2):150-157. doi: 10.1038/s41423-021-00774-w. Epub 2021 Oct 13.
10
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.阿斯利康的 COVID-19 疫苗在马拉维既往感染过 SARS-CoV-2 的成年人中诱导出强大的广泛交叉反应性抗体应答。
BMC Med. 2022 Mar 28;20(1):128. doi: 10.1186/s12916-022-02342-z.

引用本文的文献

1
Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series.COVID-19 的先天免疫反应:临床病例系列中 NK 淋巴细胞的单细胞多组学特征。
Cell Commun Signal. 2024 Oct 15;22(1):496. doi: 10.1186/s12964-024-01867-5.
2
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).实体器官移植受者和艾滋病毒感染者接种第三剂严重急性呼吸综合征冠状病毒2疫苗后的抗体反应(COVERALL-2)。
Open Forum Infect Dis. 2023 Nov 3;10(11):ofad536. doi: 10.1093/ofid/ofad536. eCollection 2023 Nov.
3
Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort.

本文引用的文献

1
Evolutionary insight into the emergence of SARS-CoV-2 variants of concern.对引发关注的 SARS-CoV-2 变异株出现的进化分析。
Nat Med. 2022 Jul;28(7):1357-1358. doi: 10.1038/s41591-022-01892-2.
2
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.SARS-CoV-2 奥密克戎亚变种 BA.2.12.1、BA.4 和 BA.5 的抗体逃逸
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
3
Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies.
印度尼西亚新冠病毒自然感染和疫苗接种所引发抗体的中和能力比较:一项前瞻性队列研究
Antibodies (Basel). 2023 Sep 21;12(3):60. doi: 10.3390/antib12030060.
4
Predictive potential of SARS-CoV-2 RNA concentration in wastewater to assess the dynamics of COVID-19 clinical outcomes and infections.污水中 SARS-CoV-2 RNA 浓度对评估 COVID-19 临床结局和感染动态的预测潜力。
Sci Total Environ. 2023 Aug 15;886:163935. doi: 10.1016/j.scitotenv.2023.163935. Epub 2023 May 8.
5
Clinical application of SARS-CoV-2 antibody detection and monoclonal antibody therapies against COVID-19.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体检测及抗2019冠状病毒病单克隆抗体疗法的临床应用
World J Clin Cases. 2023 Apr 6;11(10):2168-2180. doi: 10.12998/wjcc.v11.i10.2168.
用于快速评估抗 SARS-CoV-2 抗体中和活性的均相替代病毒中和测定法。
Nat Commun. 2022 Jul 1;13(1):3716. doi: 10.1038/s41467-022-31300-9.
4
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.奥密克戎 BA.1 和 BA.2 变异株对疫苗诱导的血清和治疗性单克隆抗体的耐药性。
Viruses. 2022 Jun 18;14(6):1334. doi: 10.3390/v14061334.
5
Longitudinal dynamics of SARS-CoV-2 anti-receptor binding domain IgG antibodies in a wide population of health care workers after BNT162b2 vaccination.BNT162b2 疫苗接种后广泛医护人群中 SARS-CoV-2 受体结合域 IgG 抗体的纵向动力学。
Int J Infect Dis. 2022 Sep;122:174-177. doi: 10.1016/j.ijid.2022.05.061. Epub 2022 May 31.
6
Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine.接种 BNT162b2 疫苗第三剂前后抗 SARS-CoV-2 S-RBD IgG 抗体的纵向分析。
Sci Rep. 2022 May 23;12(1):8679. doi: 10.1038/s41598-022-12750-z.
7
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.LY-CoV1404(贝替洛维单抗)能有效中和 SARS-CoV-2 变体。
Cell Rep. 2022 May 17;39(7):110812. doi: 10.1016/j.celrep.2022.110812. Epub 2022 Apr 25.
8
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.异源接种灭活疫苗后再接种 mRNA 加强针可诱导针对 SARS-CoV-2 奥密克戎变异株的强烈免疫应答。
Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.
9
The clinical progress of mRNA vaccines and immunotherapies.mRNA 疫苗和免疫疗法的临床进展。
Nat Biotechnol. 2022 Jun;40(6):840-854. doi: 10.1038/s41587-022-01294-2. Epub 2022 May 9.
10
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.